Discussion on kaposi sarcoma in the HAART Era.

Grace Sulica*

Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Introduction

Kaposi Sarcoma (KS) is a complex and multifaceted malignancy that affects various populations worldwide. It gained prominence during the early years of the HIV/AIDS epidemic, as it was identified as one of the defining opportunistic infections associated with advanced immunosuppression. With the introduction of Highly Active Antiretroviral Therapy (HAART) in the mid-1990s, the landscape of HIV/AIDS management underwent a significant transformation. This article delves into the impact of HAART on Kaposi Sarcoma, examining the changes in epidemiology, clinical features, treatment strategies, and challenges faced in the HAART era [1].

The impact of HAART on Kaposi Sarcoma epidemiology

The introduction of HAART revolutionized the treatment of HIV/AIDS, leading to improved immune function, decreased viral replication, and increased CD4 cell counts. One of the notable effects of HAART was a reduction in the incidence and severity of opportunistic infections, including Kaposi Sarcoma. Prior to HAART, KS was a frequent manifestation of advanced HIV infection, particularly in individuals with low CD4 cell counts. However, with the widespread use of HAART, there was a marked decline in the incidence of KS and a shift towards milder and more localized forms of the disease [2].

Clinical features and presentation in the HAART Era

The clinical features of Kaposi Sarcoma in the HAART era have undergone changes compared to the pre-HAART era. In the pre-HAART era, KS often presented as extensive cutaneous lesions, affecting multiple body sites and frequently involving internal organs. In contrast, in the HAART era, localized cutaneous KS lesions have become more common, with fewer instances of systemic involvement. Moreover, the severity of KS-associated symptoms, such as pain and edema, has diminished, contributing to an improved quality of life for affected individuals.

Treatment strategies in the HAART Era

The management of Kaposi Sarcoma in the HAART era involves a multidisciplinary approach, with collaboration between oncologists, infectious disease specialists, and HIV clinicians. The primary therapeutic goal is to control the HIV infection through adherence to HAART, as this significantly improves immune function and helps control KS progression. Additionally, localized therapies, such as surgical excision, cryotherapy, or radiation therapy, are effective in treating localized KS lesions and relieving associated symptoms. Systemic therapy, including chemotherapy and immunotherapy, remains an important component of KS treatment when there is extensive cutaneous involvement or systemic disease. Liposomal anthracyclines, such as liposomal doxorubicin, are commonly used in the HAART era due to their efficacy and relatively lower toxicity compared to conventional chemotherapy agents. Immunotherapy, such as immune checkpoint inhibitors, has also shown promise in treating advanced KS by enhancing the immune system's ability to recognize and destroy cancer cells [3].

Challenges in the HAART Era

Despite the significant progress made in managing Kaposi Sarcoma in the HAART era, several challenges persist. Firstly, some individuals may present with KS as the initial manifestation of HIV infection, emphasizing the importance of early HIV testing and initiation of HAART. Secondly, immune reconstitution inflammatory syndrome (IRIS) can occur in some patients after starting HAART, resulting in an exacerbation of KS lesions due to the immune system's reactivation. Prompt recognition and appropriate management of IRIS-related KS are essential to avoid unnecessary interventions. Another challenge is the development of drug resistance. Long-term use of HAART can lead to the emergence of drug-resistant HIV strains, potentially compromising the control of both HIV infection and associated KS. Close monitoring of HIV viral load and timely adjustments to antiretroviral therapy regimens are crucial in mitigating the risk of drug resistance [4].

Additionally, the optimal timing and sequence of systemic therapies for KS in the HAART era remain areas of active research and debate. Balancing the potential toxicities of chemotherapy or immunotherapy with the need to control KS progression is a complex decision that requires careful consideration and individualized treatment plans. Furthermore, access to healthcare and antiretroviral therapy, particularly in resource-limited settings, continues to be a challenge. Disparities in healthcare infrastructure, availability of medications, and socioeconomic factors can impact the timely diagnosis and management of both HIV/AIDS and KS. The advent of HAART has transformed the landscape of HIV/AIDS management and had a significant impact on the epidemiology, clinical features, and treatment of Kaposi Sarcoma. The reduced incidence and severity of KS,

***Correspondence to:** Grace Sulica, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA, E-mail: sulica.gr54@gmail.com

***Received:** 24-Apr-2023, Manuscript No. AAPMT-23-98565; **Editor assigned:** 27-Apr-2023, PreQC No. AAPMT-23-98565(PQ); **Reviewed:** 11-May-2023, QC No. AAPMT-23-98565; **Revised:** 15-May-2023, Manuscript No. AAPMT-23-98565(R); **Published:** 22-May-2023, DOI: 10.35841/aapmt-7.3.147*

***Citation:** Sulica G. Discussion on kaposi sarcoma in the HAART Era. J Pain Manage Ther. 2023;7(3):147*

coupled with improved immune function and control of HIV replication, have resulted in better outcomes and an enhanced quality of life for individuals living with HIV/AIDS [5].

Conclusion

Localized therapies and systemic treatments, including chemotherapy and immunotherapy, have contributed to effective KS management in the HAART era. However, challenges such as delayed diagnosis, immune reconstitution inflammatory syndrome, drug resistance, and limited access to healthcare persist and warrant ongoing research and intervention. Continued efforts are needed to ensure widespread availability of HAART, early detection of HIV infection, and optimal management of KS in the context of HIV/AIDS. Advancements in understanding the pathogenesis of KS and the development of targeted therapies hold promise for further improving outcomes and addressing the unique challenges faced by individuals with HIV-associated Kaposi Sarcoma in the HAART era.

References

1. Tam HK, Zhang ZF, Jacobson LP, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer. 2002;98(6):916-22.
2. Holkova B, Takeshita K, Cheng DM, et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol. 2001;19(18):3848-51.
3. Paparizos VA, Kyriakis KP, Papastamopoulos V, et al. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J Acquir Immune Defic Syndr. 2002;30(2):257-8.
4. Stebbing J, Wildfire A, Portsmouth S, et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations. Ann Oncol. 2003;14(11):1660-6.
5. Kitahata MM, Dillingham PW, Chaiyakunapruk N, et al. Electronic human immunodeficiency virus (HIV) clinical reminder system improves adherence to practice guidelines among the University of Washington HIV Study Cohort. Clin Infect Dis. 2003;36(6):803-11.

Citation: *Sulica G. Discussion on kaposi sarcoma in the HAART Era. J Pain Manage Ther. 2023;7(3):147*